Neurosciences
Our Team
Dr. Sreekanta S
Sr. Neurologist
Dr. Krishna K N
Sr.Neurosurgeon
Dr. Vikram Kamath
Sr. Neurologist
Dr. Dilip G
Sr.Spine surgeon
Dr. Ganesh K Murthy
Sr. Neurosurgeon
Dr.Sanjiv C C
Sr. Neurologist
Dr. Arun L Naik
Sr. Neurosurgeon
Dr. Abhilash Bansal
Neurosurgeon
  
 
Dr. K. Kartik Revanappa
Associate Consultant Neurosurgeon
Dr. Prashanth L K
Neurologist & Movement Disorder Specialist
 
  
Dr. Rakesh Jadav
Neurologist
 
 
>> >> Dr. Prashanth L K

Dr. Prashanth L K

MBBS, DM( Neurology),Fellowship in Movement Disorder(Toronto)

Consultant Neurologist
Specialist: Parkinson's Disease & Other Movement Disorders

  +91 984 526 6033

 

Dr. Prashanth LK, is one of the very few Neurologists in India who is  further sub-specialized in Parkinson's disease and other Movement disorders. He also has advanced  training in management of Deep brain stimulation (DBS). He is currently working as Consultant Neurologist and Movement Disorder Specialist at Apollo Hospitals, Bengaluru.

 

 

Experience

           Dr. Prashanth LK obtained his Medical degree from Mahadevappa Rampure Medical College(MRMC) in Gulbarga and completed residency in Neurology from National institute of Mental Health and Neurosciences (NIMHANS), Bengaluru. Following his completion of Residency in 2008, he was selected for the Fellowship in Movement disorders at the Movement Disorders Center, Toronto Western Hospital, University of Toronto, Canada in 2009. Here he was trained under Professor. Anthony. E. Lang, who is a world renowned leader in Movement Disorders.

           During this tenure, Dr. Prashanth LK acquired extraordinary skills in recognizing and managing various movement disorders. He was also trained in utilizations of botulinum toxin for various Neurological diseases. He was trained by Dr. Elena Moro, who is well renowned for surgical management of Movement disorders patients.

         In addition to assessment and management of Movement disorders patients for surgeries, he also acquired surgical planning and operative assessment.

Specialty Interest

  • Parkinson's Disease and Other related Movement Disorders
  • Botulinum procedures for neurological disorders
  • Surgical Management of Movement Disorders (Deep Brain Stimulation-DBS)

Research & Publications

Publications:

Dr. Prashanth LK, has been involved in various National, and International research work. In addition to numerous National and International presentations, his research publications in peer reviewed journals include:
  • Sinha S, Vasudev MK, Taly AB, Arunodaya GR, Ravishankar S, Prashanth LK, Venugopal KS, Swamy HS. Wilson’s disease: Cranial MRI observations and clinical correlation in 74 patients From India. Neurology (USA) 2003; 60: 288-289.
  • Sinha S, Taly AB, Prashanth LK, Arunodaya GR, Swamy HS. Successful pregnancies and abortions in symptomatic and asymptomatic Wilson's disease. J Neurol Sci 2004;217(1):37-40.
  • Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS. Wilson's disease: diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry 2004;75(6):907-909
  • Sinha S, Prashanth LK, Mahadevan A, Satish S, Ravishankar S, Arunodaya GR, et al. Co-occurrence of Wilson's disease and glioblastoma multiforme--is it a chance association? Clin Neuropathol 2004;23(5):241-244.
  • Meenakshi-Sundaram S, Sinha S, Rao M, Prashanth LK, Arunodaya GR, Rao S, et al. Cardiac involvement in Wilson's disease--an electrocardiographic observation. J Assoc Physicians India 2004;52:294-296.
  • Sinha S, Ravishankar S, Taly AB, Arunodaya GR, Prashanth LK, Vasudev MK. Wilson’s disease: A 31P and 1H MR spectroscopic study. Neurology 2004; 62(5): 539-540
  • Sinha S, Christopher R, Prashanth LK, Vidya N, Arunodaya G R, S Rao, Taly AB. Malonialdhyde levels in Wilson’s disease? Annals of Indian Academy of Neurology, 2004;7(4):507-510.
  • Prashanth LK, Sinha S. Pupil. Chakravorty A(ed) In Neurophthalmology. Journal of Association of eastern India, Kolkata, 2004: 406-423.
  • Sinha S, Christopher R, Arunodaya GR, Prashanth LK, Gopinath G, Swamy HS, et al. Is low serum tocopherol in Wilson's disease a significant symptom? J Neurol Sci 2005;228(2):121-123.
  • Prashanth LK, Taly AB, Sinha S, Ravishankar S, Arunodaya GR, Vasudev MK, et al. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease. QJM 2005;98(8):557-563.
  • Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS. Wilson’s disease: Diagnostic errors and clinical implications. Psychiatric review 2005; 5: 91-93.
  • Prashanth LK, Taly AB, Ravi V, Sinha S, Arunodaya GR. Adult onset subacute sclerosing panencephalitis: clinical profile of 39 patients from a tertiary care centre. J Neurol Neurosurg Psychiatry 2006;77(5):630-633.
  • Prashanth LK, Taly AB, Ravi V, Sinha S, Rao S. Long term survival in subacute sclerosing panencephalitis: an enigma. Brain Dev 2006;28(7):447-452.
  • Sinha S, Taly AB, Ravishankar S, Prashanth LK, Venugopal KS, Arunodaya GR, et al. Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 2006;48(9):613-621.
  • Prashanth LK, Taly AB, Sinha S, Ravi V. Subacute sclerosing panencephalitis (SSPE): an insight into the diagnostic errors from a tertiary care university hospital. J Child Neurol 2007;22(6):683-688.
  • Sinha S, Taly AB, Prashanth LK, Ravishankar S, Arunodaya GR, Vasudev MK. Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients. Br J Radiol 2007;80:744-749.
  • Sinha S, Taly AB, Ravishankar S, Prashanth LK, Vasudev MK. Central Pontine Signal Changes in Wilson Disease: Distinct MRI Morphology and Sequential Changes with De-Coppering Therapy. J of Neuroimaging. 2007; 17:286-291
  • Shanmugiah A, Sinha S, Taly AB, Prashanth LK, Tomar M, Arunodaya GR, Janardhana Reddy YC, Khanna S. Psychiatric Manifestations in Wilson’s disease: A Cross-Sectional Analysis. J Neuropsychiatry Clin Neurosci. 2008;20:81-85.
  • Shanmugiah A, Sinha S, Taly AB, Prashanth LK, Tomar M, Arunodaya GR, Janardhana Reddy YC, Khanna S. Psychiatric Manifestations in Wilson’s disease: A Cross-Sectional Analysis. J Neuropsychiatry Clin Neurosci. 2008;20:81-85.
  • Komal Kumar RN, Taly AB, Nair KPS, Sinha S, Prashanth LK, Vidya N, Arunodaya GR, Rao S. Quality of Life in Wilson’s disease. Annals of Indian Academy of Neurology. 2008;11:37-43.
  • Prashanth LK, Veerendrakumar M, Gayathri N, Subbukrishna DK. How many motor unit potentials to sample in diagnostic needle EMG? Clinical Neurophysiology. 2009;120 (Suppl-1):S23-S24.
  • Veerendrakumar M, Gayathri N, Subbukrishna DK, Prashanth LK. Manual Scannin EMG study of variability of motor unit potential parameters. Clinical Neurophysiology. 2009;120 (Suppl-1):S40.
  • Taly AB, Prashanth LK, Sinha S. Wilson's disease: An Indian perspective. Neurol India. 2009 Sep-Oct;57(5):528-40.
  • Prashanth LK, Sinha S, Taly AB, A Mahadevan, Vasudev MK, Shankar SK. Spectrum of epilepsy in Wilson's disease with electroencephalographic, MR imaging and pathological correlates. J Neurol Sci. 2010 Apr 15;291(1-2):44-51.
  • Sinha S, Taly AB, Ravishankar S, Prashanth LK, Vasudev MK. Wilson's disease: (31)P and (1)H MR spectroscopy and clinical correlation. Neuroradiology. 2010 Feb 20. [Epub ahead of print].
  • Prashanth LK, Sinha S, Taly AB, Vasudev MK. Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord. 2010 Apr 30;25(6):672-8.
  • Prashanth LK, Fox S, Meissner WG. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol. 2011;98:31-54.
  • Lang AE, Prashanth LK, Ghosh S, Elahi B, Chen R. Extreme task specificity: is it dystonia or another form of motor programming abnormality? Mov Disord. 2012 Aug;27(9):1202-1203.
  • Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, Shah BB, Fox S, Prashanth LK, Phielipp N, Lang AE. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84(2):130-135.
  • Fasano A, Valadas A, Bhatia KP, Prashanth LK, Lang AE, Munhoz RP, Morgante F, Tarsy D, Duker AP, Girlanda P, Bentivoglio AR, Espay AJ. Psychogenic facial movement disorders: clinical features and associated conditions. Mov Disord. 2012 Oct;27(12):1544-51.
  • Connolly BS, Prashanth LK, Shah BB, Marras C, Lang AE. A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3. Neurology. 2012 Nov 27;79(22):2218.
  • Petrovic IN, Ling H, Asi Y, Ahmed Z, Kukkle PL, Hazrati LN, Lang AE, Revesz T, Holton JL, Lees AJ. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 2012 Aug;27(9):1186-90.
  • Chan HF, Kukkle PL, Merello M, Lim SY, Poon YY, Moro E. Amantadine improves gait in PD patients with STN stimulation. Parkinsonism Relat Disord. 2013 Mar;19(3):316-9.

Research:

  • A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist.
  • A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy in subjects with early idiopathic Parkinson's disease treated with a stable dose of a single dopamine agonist. Protocol no: 27938
  • Famotidine for the treatment of levodopa-induced dyskinesia: An "N- of-1" Study
  • A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.
  • Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
  • Validation of Dyskinesia Rating Scales
  • “Wilson’s Disease: Clinical, Imaging and Functional Outcome with Long -Term Zinc and Penicillamine Therapy”, NIMHANS, Bangalore, India

Book Appointment online